報價延遲最少15分鐘:2024/12/24 12:22 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.46 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.98/-2.88
|
|
企業價值
126.67M
|
| 資產負債 |
|
每股賬面淨值
0.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:22 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidiveforthe prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. |